DURHAM, N.C., May 22, 2015 (GLOBE NEWSWIRE) -- Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, announced today that it was awarded the Best Late Stage Product Development Company award by the Triangle Business Journal and accounting firm BDO. Parion joins the third-annual class of Life Science Award winners and received the award at an event held yesterday in Cary North Carolina. The Life Sciences awards recognize both individuals and research organizations that are breaking ground in the field. This encompasses a number of areas, including biology, biotechnology, genomics, neuroscience, and pharmacology.
“This year’s list of winners reflect the power, influence and intellect present in our communities within this sector,” says Bryan Michael Hamilton, publisher of the Triangle Business Journal. "In the Triangle, the life sciences industry continue to attract companies and individuals whose work and research are being monitored and revered across the globe. This sector continues to lead the Triangle's economic resurgence."
The award was accepted by Paul Boucher, the President and Chief Executive Officer of Parion Sciences. Paul stated “I am pleased to accept this award on behalf of our dedicated employees and founders. We truly appreciate the recognition and support as we continue to progress our innovative programs through the clinic and potentially to patients in need of new therapies.”
About Parion Sciences
Parion Sciences is a development stage biopharmaceutical company dedicated to research, development and commercialization of treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the eye or airway. Parion has a diverse pipeline of pre-clinical and clinical candidates for the treatment of these diseases via distinctive mechanisms of action and approaches. Parion is at the forefront of ENaC development and is leveraging our scientific expertise in epithelial biology to expand our platforms and novel chemical compounds into new indications to treat mucosal defects. Parion has received support and grant funding from the National Institutes of Health and the Cystic Fibrosis Foundation Therapeutics, Inc. For more information, please see our website at www.Parion.com.
Paul Boucher President & CEO, Parion Sciences 919-313-1195 firstname.lastname@example.org
Source: Parion Sciences